• UVA Health's Institutional Review Board has approved enrolment in Imricor's VISABL-AFL clinical trial
• UVA Health is the second U.S. site for the trial, with procedures expected to commence in February
• The Principal Investigator for VISABL-AFL at UVA Health is Dr. Kenneth Bilchick

Imricor Medical Systems, Inc. (ASX: IMR) announced that the Institutional Review Board (IRB) of the University of Virginia (UVA) Health Medical Center has approved UVA Health's enrolment in Imricor's VISABL-AFL clinical trial. Imricor personnel performed a Site Initiation Visit with five UVA Health physicians and UVA Health's Clinical Research Coordinator team on 11 December. Next steps include final approval of the agreed-upon site research contract, expected in the coming days, followed by site installation and clinical training, both planned for January after the holidays. Procedures are expected to commence in February. The Principal Investigator (PI) for VISABL-AFL at UVA Health is Dr. Kenneth Bilchick, Electrophysiologist, Professor of Cardiology, and Director of Electrophysiology Research at UVA Health. UVA Health is an academic health system associated with the University of Virginia in Charlottesville, Virginia, USA. The UVA Health University Medical Center includes a 600-plus-bed hospital and nationally ranked specialty programs. Imricor's Chair and CEO, Steve Wedan, stated that the speed at which UVA Health has progressed from initial introduction to clearing IRB has been outstanding, and that UVA Health is just the first of several U.S. sites expected to join VISABL-AFL, helping to ensure that Imricor's enrolment and FDA processes remain on schedule.